Ipamorelin/Tesamorelin Blend: Dosage, Benefits & Side Effects
By Peptide Assistant Editorial Team · · · 9 sources cited
Overview
The Ipamorelin/Tesamorelin blend combines Ipamorelin (GHRP) with Tesamorelin (a GHRH analog with FDA-approved status for visceral adiposity reduction). This blend is specifically popular for body composition optimization, particularly visceral fat reduction, leveraging the GHRH+GHRP synergy with Tesamorelin's demonstrated fat-targeting properties.
Mechanism of Action
Like other GHRH+GHRP combinations, this blend exploits synergistic GH release through dual-pathway activation. Tesamorelin is a modified GHRH(1-44) with a trans-3-hexenoic acid group that extends its half-life and receptor binding. It activates pituitary GHRH receptors while Ipamorelin simultaneously activates GHS-R1a, producing amplified GH pulses. Tesamorelin has specific FDA-studied evidence for reducing visceral adipose tissue (VAT) — the metabolically dangerous fat surrounding abdominal organs. This is thought to involve preferential lipolytic signaling in visceral adipocytes through GH-mediated activation of hormone-sensitive lipase and enhanced beta-adrenergic sensitivity in visceral fat.
Ipamorelin/Tesamorelin Blend Benefits: What the Research Shows
- Tesamorelin is FDA-approved (Egrifta) for reduction of excess abdominal fat in HIV-infected patients with lipodystrophy
- The pivotal phase 3 trial showed tesamorelin reduced visceral adipose tissue by 15.2% over 26 weeks vs. placebo (New England Journal of Medicine, 2007), and the pooled analysis of both phase 3 trials (n=806) gave a 15.4% treatment effect
- Tesamorelin reduced visceral fat and triglycerides with no clinically meaningful change in glucose in the trials, though the label reports more treated patients than placebo reaching an HbA1c of 6.5% or higher
- Combined GHRH and GHRP infusions produce synergistic GH release beyond either component alone in men, although the pairing studied was GHRH with GHRP-2, not tesamorelin with ipamorelin
- IGF-I rose 81% from baseline on tesamorelin in the pivotal trial; no study has given tesamorelin together with ipamorelin
Ipamorelin/Tesamorelin Blend Dosage
- Standard dose: Tesamorelin 1–2 mg + Ipamorelin 100–200 mcg, once daily subcutaneous injection
- Optimal timing: before bed or upon waking (fasted state)
- FDA-approved tesamorelin dose: 1.4 mg daily (Egrifta SV) or 1.28 mg daily (Egrifta WR) for HIV-associated lipodystrophy
- Cycle: 12–26 weeks for visceral fat reduction (per FDA study duration), then reassess
- Inject subcutaneously into abdominal area
- Must be fasted — food blunts GH response
- Some protocols add a second Ipamorelin-only dose at another time point for additional GH pulses
Disclaimer: Dosing information is compiled from research literature and community protocols for educational purposes only. This is not medical advice. Always consult a qualified healthcare provider before starting any peptide protocol.
Ipamorelin/Tesamorelin Blend Side Effects & Safety
Known Side Effects
- Injection site reactions: erythema, pruritus, swelling (most common with tesamorelin)
- Peripheral edema and fluid retention
- Joint pain (arthralgia) — GH-mediated
- Paresthesia (tingling/numbness in extremities)
- Potential for mild glucose elevation with prolonged use — monitor HbA1c
- Myalgia (muscle pain)
Safety Profile
Tesamorelin has FDA-approved safety data, the most rigorous available for any GHRH analog, but it was never studied in combination with a GHRP, so the blend itself has none. The phase 3 trials and their 26-week extension followed patients to 52 weeks without clinically significant glucose changes. Tesamorelin should not be used in patients with disruption of the hypothalamic-pituitary axis (e.g., from hypophysectomy, pituitary tumor), active malignancy, pregnancy, or known hypersensitivity. IGF-1, glucose, and HbA1c should be monitored every 3–6 months. What ipamorelin adds is untested: its selectivity was shown in rats and swine, its only controlled human trial was a 7-day postoperative study that missed its endpoint, and FDA concluded in 2024 that compounding with ipamorelin may raise safety concerns. Discontinue if IGF-1 rises above the age-adjusted upper limit of normal.
What to Expect
Weeks 1–4: Improved sleep quality. Subtle improvements in energy and recovery. Mild water retention may occur initially. Weeks 5–12: Progressive visceral fat reduction becomes measurable — waist circumference decreases. Lean mass improves. Skin quality improves. Triglycerides may improve. Weeks 13–26: Continued visceral fat reduction toward maximum benefit. Body composition optimized. IGF-1 elevated 40–80% above baseline. Full anti-aging benefits of optimized GH are realized. Benefits persist for several weeks after discontinuation but gradually return toward baseline.
Common Stacks
AOD-9604
AOD-9604 adds GH-fragment-mediated lipolysis that complements tesamorelin's visceral fat reduction for maximum fat loss
BPC-157
BPC-157 leverages the enhanced GH environment for accelerated recovery alongside body composition improvement
MOTS-c
MOTS-c activates AMPK and enhances metabolic flexibility, complementing the GH-driven fat oxidation of this blend
Storage & Handling
Store lyophilized blend at 2–8°C for up to 12 months or -20°C for longer storage. Reconstitute per vendor instructions with bacteriostatic water. Refrigerate reconstituted solution and use within 3–4 weeks. Tesamorelin is moderately sensitive to heat — protect from temperatures above 25°C.
Pricing & Available Variants
Prices sourced from peptides.gg marketplace. Prices may vary.
References
- EGRIFTA WR (tesamorelin) for injection: full prescribing information. Theratechnologies, via DailyMed. 2025.
- EGRIFTA SV (tesamorelin) for injection: full prescribing information. Theratechnologies, via DailyMed. 2024.
- Falutz J, Allas S, Blot K, et al. Metabolic effects of a growth hormone-releasing factor in patients with HIV. N Engl J Med. 2007.
- Falutz J, Mamputu JC, Potvin D, et al. Effects of tesamorelin (TH9507), a growth hormone-releasing factor analog, in human immunodeficiency virus-infected patients with excess abdominal fat: a pooled analysis of two multicenter, double-blind placebo-controlled phase 3 trials with safety extension data. J Clin Endocrinol Metab. 2010.
- Falutz J, Allas S, Mamputu JC, et al. Long-term safety and effects of tesamorelin, a growth hormone-releasing factor analogue, in HIV patients with abdominal fat accumulation. AIDS. 2008.
- Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998.
- Beck DE, Sweeney WB, McCarter MD. Prospective, randomized, controlled, proof-of-concept study of the Ghrelin mimetic ipamorelin for the management of postoperative ileus in bowel resection patients. Int J Colorectal Dis. 2014.
- FDA Briefing Document, Pharmacy Compounding Advisory Committee: evaluation of ipamorelin-related bulk drug substances. U.S. Food and Drug Administration. 2024.
- Veldhuis JD, Bowers CY. Determinants of GH-releasing hormone and GH-releasing peptide synergy in men. Am J Physiol Endocrinol Metab. 2009.
Related Peptides
Track Ipamorelin/Tesamorelin Blend in Your Protocol
Log your Ipamorelin/Tesamorelin Blend doses, track consistency, and monitor your protocol with Peptide Assistant — completely free.
Start Tracking Free